BioVaxys Technology Corp.

DB:5LB Stock Report

Market Cap: €10.6m

BioVaxys Technology Management

Management criteria checks 4/4

BioVaxys Technology's CEO is Chris Passin, appointed in Jan 2016, has a tenure of 9.08 years. total yearly compensation is CA$126.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 6.72% of the company’s shares, worth €715.08K. The average tenure of the management team and the board of directors is 9.1 years and 3.8 years respectively.

Key information

Chris Passin

Chief executive officer

CA$126.0k

Total compensation

CEO salary percentage100.0%
CEO tenure9.1yrs
CEO ownership6.7%
Management average tenure9.1yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Passin's remuneration changed compared to BioVaxys Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jul 31 2024n/an/a

-CA$4m

Apr 30 2024n/an/a

-CA$5m

Jan 31 2024n/an/a

-CA$6m

Oct 31 2023CA$126kCA$126k

-CA$8m

Jul 31 2023n/an/a

-CA$14m

Apr 30 2023n/an/a

-CA$12m

Jan 31 2023n/an/a

-CA$11m

Oct 31 2022CA$126kCA$126k

-CA$12m

Jul 31 2022n/an/a

-CA$6m

Apr 30 2022n/an/a

-CA$6m

Jan 31 2022n/an/a

-CA$6m

Oct 31 2021CA$126kCA$126k

-CA$6m

Jul 31 2021n/an/a

-CA$5m

Apr 30 2021n/an/a

-CA$4m

Jan 31 2021n/an/a

-CA$3m

Oct 31 2020CA$10kCA$10k

-CA$1m

Compensation vs Market: Chris's total compensation ($USD88.23K) is below average for companies of similar size in the German market ($USD461.47K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Passin (52 yo)

9.1yrs

Tenure

CA$126,000

Compensation

Mr. James Christopher Passin, also known as Chris, serves as an Independent Director at St-Georges Eco-Mining Corp. since June 2023. He Co-founded BioVaxys Technology Corp. (Formerly Lions Bay Mining Corp....

Leadership Team

NamePositionTenureCompensationOwnership
James Passin
Co-Founder9.1yrsCA$126.00k6.72%
€ 715.1k
Kenneth Kovan
Co-Founder9.1yrsCA$241.99k3.28%
€ 348.7k
David Berd
Co-Founder & Chief Medical Officer9.1yrsno data1.75%
€ 186.3k
Christopher Cherry
Chief Financial Officerless than a yearno datano data

9.1yrs

Average Tenure

61yo

Average Age

Experienced Management: 5LB's management team is seasoned and experienced (9.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Passin
Co-Founder4.4yrsCA$126.00k6.72%
€ 715.1k
Anthony John Dutton
Independent Director2.8yrsCA$86.88k0.44%
€ 46.6k
Shmuel Farhi
Member of Scientific Advisory Board4.1yrsno datano data
Craig Loverock
Independent Director1.8yrsCA$33.50k0.24%
€ 25.1k
Kartik Chandran
Member of Scientific Advisory Board4yrsno datano data
Charles Dunton
Member of Advisory Board3.8yrsno datano data
Adam Coutts
Member of Advisory Board3.8yrsno datano data
Yvelise Barrios
Scientific Adviser3.5yrsno datano data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Board: 5LB's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 18:48
End of Day Share Price 2025/02/07 00:00
Earnings2024/07/31
Annual Earnings2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioVaxys Technology Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.